In the univariate analyses of HIV-infected subjects, a lower FMD was significantly associated with higher insulin resistance (by both HOMA-IR and Belfiore OGTT index), greater consumption of alcohol (≥1 drink/day), and higher baseline brachial artery diameter (P < 0.05 for all). In HIV seronegatives, higher insulin resistance, brachial artery diameter, and lower systolic blood pressure were predictive of lower FMD (P < 0.05 for all). Among HIV-infected and seronegative subjects, there was a significant correlation between CIMT and traditional cardiac risk factors including male sex, older age, history of hypertension, lower HDL cholesterol, higher glucose, higher insulin resistance, higher trunk/limb fat ratio (HIV-infected subjects with DEXA data), and the presence of an increasing number of metabolic syndrome criteria (P < 0.05 for all). In multivariate analyses (Table 3) among HIV-infected subjects, higher insulin resistance, greater consumption of alcohol, and higher resting brachial artery diameter remained significant independent predictors of FMD (adj. r 2 = 0.40, P < 0.001 for model). History of hypertension, higher trunk/limb fat ratio, and insulin resistance remained significant predictors of CIMT (adj. r 2 = 0.46, P < 0.001 for model). There was a strong correlation between the HOMA-IR and Belfiore OGTT indices (r = −0.82, P ≤ 0.001).
To further explore a potential confounding effect between ritonavir and insulin resistance, the relationship between current protease inhibitor use and brachial FMD or CIMT was also examined. All subjects on a protease-inhibitor-based regimen were on a ritonavir-boosted regimen (76% were on atazanavir/ritonavir). There was no significant association between either brachial FMD or CIMT and current use of a ritonavir-boosted protease inhibitor. Additionally, the cumulative exposure to HAART, as well as the cumulative exposure to individual drug classes (nucleosides, NNRTIs, protease inhibitors) revealed no significant association with either brachial FMD or CIMT. Studies have also found an association between thymidine analogue use and insulin resistance [20–22], but in the present study there was no significant correlation between cumulative exposure/use ever of zidovudine or stavudine and HOMA-IR/Belfiore index, brachial FMD, or CIMT. There have also been conflicting data with regard to effects of body fat changes (lipoatrophy) on FMD [13,23], but in our study we found no significant association between appendicular fat, trunk fat, or trunk/limb fat ratio and FMD. Finally, there was no significant correlation between HIV disease activity indicators (i.e., current/nadir CD4 cell count, HIV RNA, duration of HIV) and CIMT or brachial FMD. Overall, there were modest, significant correlations between FMD and CIMT (r = −0.40, P < 0.01) and between CIMT and 10-year Framingham score (r = 0.50, P < 0.01). There were no significant correlations between FMD and Framingham score, between FMD and hsCRP, and between CIMT and hsCRP. Traditional risk factors utilized in the Framingham risk score (age, smoking, HDL and total cholesterol, blood pressure) were more predictive of CIMT (r = 0.55, P = 0.01) than brachial FMD (r = 0.25, P = NS).
The results of this study of HIV-infected subjects on modern HAART regimens and with well controlled viremia demonstrate no significant differences in either brachial FMD or CIMT compared with seronegative controls. Higher insulin resistance was a significant predictor of lower brachial FMD and higher CIMT.
A recent study examined endothelial function in HIV-infected subjects vs. controls, and found that HIV-infected subjects had significantly impaired brachial FMD, and that current intravenous drug use was significantly associated with FMD . Although insulin resistance was not reported in that study, 63% of HIV-infected subjects had co-infection with hepatitis C, which has been associated with increased risk of insulin resistance in some [24,25] but not all studies . Injection drug users were excluded from the present study.
Recent studies of HIV-infected, therapy-naive, and uninfected persons exposed to modern drugs such as lopinavir/ritonavir or efavirenz have shown improvements in endothelial function within a short period [13,31]. In one study, endothelial function was improved 6 months after HAART initiation, although still below normal values, and was independently predicted by the decline in HIV RNA . Also, in-vitro studies of endothelial function have implicated HIV as potentially having direct and indirect effects on the endothelium, including direct infection and/or activation of endothelial cells by HIV, vascular injury as a result of chronic inflammation and immune activation, or dysregulation of the nitric oxide synthase system [32–35]. Both tat and gp120 proteins of the HIV virion may activate endothelial cells, resulting in increased expression of specific adhesion molecules (i.e., ICAM-1, E-selectin) that may contribute to endothelial dysfunction or a prothrombotic state [33–35]. Thus, it is possible that subjects in the current study had overall low cardiovascular risk due to good control of HIV viremia and adequate restoration of immunity. As only five subjects had detectable, low-level HIV viremia, we did not have statistical power to detect significant differences in CIMT/FMD due to differences in HIV viral load.
An important finding is the association of insulin resistance with both endothelial dysfunction (i.e., lower FMD) and higher CIMT in HIV-infected subjects (Table 3). Although we did not find a significant association between current protease inhibitor or thymidine analogue use and insulin resistance, brachial FMD, or CIMT, the use of specific antiretrovirals has been strongly associated with insulin resistance in other studies [3,4,20–22,27,28]. The development of insulin resistance in some patients on HAART may have important long-term implications in determining cardiovascular disease risk. The traditional Framingham risk score calculator does not adequately account for insulin resistance (it only accounts for established diabetes) and in this study we did not find a significant correlation between brachial FMD and Framingham risk score. The Framingham score has not been validated in HIV and thus determination of insulin resistance or use of endothelial function testing could be a useful adjunct in assessing long-term cardiovascular disease risk in this population. Unfortunately larger, longitudinal cohort studies rarely incorporate the use of sensitive metabolic testing such as oral glucose tolerance testing or insulin profile. We found that a simple index of insulin resistance (HOMA-IR) was a stronger predictor of brachial FMD and CIMT than more indirect assessments, such as the diagnosis of metabolic syndrome. HOMA-IR was also strongly correlated with the sensitive Belfiore OGTT index, which requires repeated measures of insulin and glucose levels during a 2-h OGTT.
There were minor limitations. This study was cross-sectional and the number of subjects was low, but still higher compared with several other endothelial function studies in HIV [11–13,36]. In addition, several HIV-infected subjects were on statin therapy, which may have a positive effect on brachial FMD and CIMT. Nevertheless, two recent studies of statin therapy in HIV found no more than a 0.7–1.2% improvement in brachial artery FMD with statin therapy [37,38], and the inclusion of statin-treated, HIV-infected subjects in the present study was felt to best reflect current standard of care for persons with HIV . When further controlling for use of lipid-lowering medication, there were still no significant differences in FMD or CIMT between HIV-infected and control groups.
In conclusion, in this HIV cohort on modern HAART and with well controlled HIV, we found no significant differences with regard to preclinical markers of cardiovascular disease risk such as endothelial function testing, CIMT, or Framingham risk score. Insulin resistance was a stronger predictor of brachial FMD and CIMT than lipid parameters, HAART regimen, indices of immune function, lifestyle factors, or body and limb adiposity. These findings suggest that insulin resistance is an important cardiovascular disease risk factor in the HIV-infected population, and that therapeutic strategies to improve insulin sensitivity may be warranted. Longitudinal studies of HIV-infected cohorts will be important to evaluate future changes in cardiovascular risk, especially as new HIV drug classes become available.
1 K23 AI065336-01 (K.E.M.), K12RR023249 (L.diF.), DK049393, DK059531, AT003083, DK056341, RR000036, RR000954, DK020579, AI025903.
We gratefully acknowledge the Barnes-Jewish Hospital Foundation for support to the Cardiovascular Imaging and Clinical Research Core Laboratory.
1. Holmberg SD, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS, HIV Outpatient Study (HOPS) investigators. Protease inhibitor drug use and adverse cardiovascular outcomes in ambulatory HIV-infected persons. Lancet 2002; 360:1747–1748.
2. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction
. N Engl J Med
3. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al
. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130–139.
4. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48–62.
5. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al
. Insulin resistance in HIV-protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999; 21:209–216.
6. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment
. N Engl J Med
7. Faulx MD, Wright AT, Hoit BD. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J 2003; 145:943–951.
8. Kuvin JT, Karas RH. Clinical utility of endothelial function testing. Circulation 2003; 107:3243–3247.
9. Juonoala M, Viikari JSA, Laitinen T, Marniemi J, Helenius H, Rönnemaa T, et al
. Interrelations between brachial endothelial function and carotid intima–media thickness in young adults. The Cardiovascular Risk in Young Finns Study. Circulation 2004; 110:2918–2923.
10. Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven D, et al
. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42:1325–1332.
11. Van Wijk JPH, de Koning EJP, Cabezas MC, Joven J, op't Roodt J, Rebelink TJ, et al
. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006; 47:1117–1123.
12. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al
. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257–262.
13. Torriani FJ, Komarow L, Cotter BR, Murphy RL, Fichtenbaum CJ, Currier JS, et al. Control of HIV viral replication is associated with rapid improvement in endothelial function sustained over 24 weeks: A5152s, a substudy of A5152
. Antivir Ther
2007; 12(Suppl 2):
L15 [Abstract O-18].
14. Currier JS, Kendall MA, Henry WK, Alton-Smith B, Torriani FJ, Tebas P, et al
. Progression of carotid-artery media thickening in HIV-infected and uninfected adults. AIDS 2007; 21:1137–1145.
15. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–419.
16. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genetics Metab 1998; 63:134–141.
17. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant CL. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109:433–438.
18. Corretti MC, Plotnick GD, Vogel RA. Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol 1995; 286:H1397–H1408.
19. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, et al
. Noninvasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. BMJ 1995; 74:247–253.
20. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002; 51:1143–1147.
21. Fleischman A, Johnsen S, Systrom DM, Mirko H, Farrar T, Frontera WR, et al
. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292:E1666–E1673.
22. van Vonderen MGA, Blümer RME, Hassink E, Sutinen J, Ackermans MT, van Agtmael MA, et al.
and the MEDICLAS study group. Persistent reduction in peripheral glucose disposal starting prior to fat distribution changes, only during first line ART with AZT/3TC/LPV/r but not NVP/LPV/r, suggests contribution of AZT/3TC to insulin resistance by a body composition-independent mechanism. Program and Abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; Sydney, Australia, July 2007 [Abstract TUPEB077].
23. Dubé MP, Shen C, Waltz JS, Greenwald ML, Mather K, Gupta SK. Relationship of body composition, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects
. Antivir Ther
2007; 12(Suppl 2):L15–L16 [Abstract O-19].
24. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, et al
. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:245–250.
25. Hadigan C, Chung R, Murray G, Purkis D, Grinspoon S. Hepatitis B and C co-infection and alanine aminotransferase are associated with increased insulin resistance and diabetes in patients with fat redistribution. Antivir Ther 2002; 7:L24.
26. Ledergerber B, Hansjakob F, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al
. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45:111–119.
27. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, et al
. Metabolic effects of indinavir in healthy HIV seronegative men. AIDS 2001; 15:11–18.
28. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871–875.
29. Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005; 150:933.e1–933.e7.
30. Hammer SM, Saag MS, Schecter M, Montaner JSG, Schooley RT, Jacobsen DM, et al
. Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006; 296:827–843.
31. Grubb JR, Dejam A, Voell J, Blackwelder WC, Sklar PA, Kovacs JA, et al
. Lopinavir–ritonavir: effects on endothelial cell function in healthy subjects. J Infect Dis 2006; 193:1516–1519.
32. Chai H, Yang H, Ya S, Li M, Lin PH, Lumsden AB, et al
. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr 2005; 40:12–19.
33. Chi D, Henry J, Kelly J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7:223–242.
34. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007; 44:493–499.
35. Paladugu R, Fu W, Conklin BS, Lin PH, Lumsden AB, Yao Q, et al
. HIV tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2003; 38:549–555.
36. Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? Q J Med 2003; 96:825–832.
37. Hürlimann D, Chenevard R, Ruschitzka F, Flepp M, Enseleit F, Béchir M, et al
. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing antiretroviral combination therapy: a randomised double blind crossover trial. Heart 2006; 92:110–112.
38. Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, et al
. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004; 147:713.
39. Dubé MP, Stein J, Aberg J, Fichtenbaum CJ, Gerber JG, Tashima KT, et al
. Guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613–627.